OCTOBER 1973 issue of CALIFORNIA PHARMACIST

## SOME MANUFACTURERS DISCLOSE SOURCES OF SUPPLY

The last issue of the California Pharmacist (September, 1973, page 5) reported the implementation of regulations which require pharmaceutical manufacturers to disclose the name and place of business of the manufacturer who produces the finished dosage form of their products. The regulation, effective July 28, 1973, provides that manufacturers must either include the names of the mixer of the final ingredients and the encapsulator or tabulator in the product's labeling and advertising material; or provide this information in response to the written or oral request of any physician, pharmacist, or their professional associations.

or any physician, piramausis, or tient professional associations.

In an effort to supply information to the profession, the California Pharmaceutical Association requested the identity of the manufacturer who mixed the final ingredients and encapsulated or tableted the finished dosage forms of products manufacturered or distributed by over lifty different companies. The results of these requests, mailed on the 15th and 16th of August, are compiled in the following table. At the time of publication, over one month past the date of writing to the manufactur-

ers, many firms have not complied with the Association's request for

Information.

Under the provisions of these regulations (Section 10386 of Title 17 of the California Administrative Code), failure to respond to requests for the identity of the manufacturer of the finished dosage form shall result in the products of the firm failing to respond being deemed misbranded. Those companies who have not responded to the Association's requests are being sent a final notice which will preceed the institution of legal proceedings against non-complying firms.

Pharmacists who have not been provided information as to the identity of the manufacturer of any prescription drug as provided for in California law, should notify the CPhA offices so that appropriate action may be taken.

The following list indicates the realize received a second and action and the control of the control of

taken.

The following list indicates the replies received at this office as of October 1, 1973. "Acknowledged request" indicates that the distributor has advised CPhA of the receipt of the request but has not supplied the name of the manufacturer of the final dosage form prior to press time.

DISTRIBUTOR	MANUFACTURER1	DATE REPLIED	DISTRIBUTOR	MANUFACTURER <sup>1</sup>	DATE REPLIED
AMPICILLIN TRIHYDRATE 250	ng Capsules		AMPICILLIN ANHYDROUS Weeth Laboratories	Wyeth Labs.	8-24-73
American Pharmaceutical Co.	No Reply	8-29-73	wyeur Laboratories	(Philadelphia, PA)	
American Quinine Products	Zenith Labs., Inc.	8-29-13		Y 100	
and the second second	(Northvale, NJ)	9-07-73			
B. F. Ascher & Co., Inc.	International Labs., Inc. <sup>2</sup> (Mayaguez, Puerto Rico)	5-07-13	BROPHENIRAMINE MALEATE		
	Beecham-Massengill Pharm.3	9-05-73	—Elixir (Dimetane) A. H. Robins Company	A. H. Robins Company	8-27-73
Ayerst Laboratories	(Piscataway, NJ)		A. H. Hobilis Company	(Richmond, VA)	
Decision Management Decim	Beecham, Inc.	9-27-73		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Beecham-Massengill Pharm. Bristol Laboratories, Div.	Bristol Labs.	8-29-73	-Sustained Release Tablets	(Dimetane Extentals)	
of Bristol-Myers Co.	(E. Syracuse, NY)		A. H. Robins Company	ICN Pharmaceuticals	8-27-73
Coastal Pharmaceutical Co.	No Reply	and provide the	A. H. Nubits Company	Strong Cobb Arner	
Columbia Medical Company	Biocraft Labs.	9-05-73		(Cincinnati, OH)	
Columbia incurcai company	(E. Paterson, NJ)		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Acres 100
Consolidated Midland Corp.	Reid Provident 4 or	8-21-73	American Deleges Tehlete	with phonylephrine and phony	propanolamir
	Zenith Labs., Inc.	机 英国家 化二二	(Dimetapp Extentabs)		
ICN Pharmaceuticals, Inc.	No Reply		A H. Robins Company	ICN Pharmaceuticals	8-27-73
Strong Cobb Arner		9-19-73	7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	Strong Cobb Arner	
Parke, Davis & Company	Replied <sup>1,3</sup>	3-13-13		(Cincinnati, OH)	
Purepac Pharmaceutical Co.	He Reply International Labs. <sup>5</sup>	8-24-73	医痛动性 化二氯化二氯化二氯化		
Rachelle Laboratories, Inc.	(Atlanta, GA)	V = 1.17	DEXAMETHASONE 0.75 mg Ta	iblets	
ni de Diene Co Inc	No Reply		CIBA Pharmaceutical Co.	No Reply	8-21-73
Sherry Pharm. Co., Inc. Smith Kline & French, Labs.			Consolidated Midland Corp.	Danbury Pharmacal <sup>4</sup> or	0-21-10
E. R. Squibb & Sons, Inc.	E. R. Squibb & Sons, Inc.	8-31-73		Cord Laboratories	8-20-73
Stayner Corporation	International Labs.	8-20-73	Merck Sharp & Dohme	acknowledged request	0.2010
Glaynor corporation	(Atlanta, GA)	11.12.22	Div. of Merck & Co., Inc.	Organon, Inc.	8-23-73
Towne, Paulsen & Co., Inc.	International Labs.	8-27-73	Organon, Inc.	Schering Corp.	9-18-73
	(Atlanta, GA)		Schering Corp.	No Reply	
	John D. Copanos & Co., Inc.		Sherry Pharm. Co., Inc. USV Pharmaceutical Corp.	USV Pharmaceutical Corp.	8-31-73
	(Battimore, MD)	ter in the second	Zenith Laboratories, Inc.	Zenith Labs., Inc.	8-20-73
	Biocraft Labs		Zeinui Laboratorico, mo.	(Northvale, NJ)6	
o substanti patri di	(E. Paterson, NJ)				
West-ward, Inc.	No Reply Biocraft Labs	9-06-73	하는 경기 중시 하는데	(Continued	on page 8
Wolins Pharmacal Corp.	DIOCIAII Lave				1.0